title: Enhanced presence of NGF and mast cells number in nasal cavity after autologous stimulation: relation with sensorineural hearing deficit.
abstract: OBJECTIVE
  Nerve growth factor (NGF) is a neurotrophin which promote and regulate the survival of neurons in the peripheral nervous system. We aimed to evaluate the nasal NGF expressions of mast cells in healthy patients after stimulation with sterilized isotonic solution delivered at high pressure.
  
  
  METHODS
  The first part of the study was made with 21 voluntary individuals. The middle third of the inferior turbinate epithelial cells on the right nostril was scraped using a sterile curette and indicated as (pre), than a spray of sterilized isotonic solution at high pressure on the left nostril was delivered and 25 minutes later a similar stimulation was delivered on the same nostril. The stimulation was made with a specific spray. The middle third of the inferior turbinate epithelial cells on the left nostril was scraped using a sterile curette and indicated as (post).
  
  
  RESULTS
  Forced nasal stress induced by local delivery of high pressure physiological solution causes an increase in the number of mast cells and enhances level of NGF in the nasal fluid compared to the control subjects. So based on the first part of our study, since NGF is universally known as effective in protection and repairing of neural cells damage, we started the second part and gave a treatment on the same patients, to increase NGF levels with a six months daily therapy and observed the variations in Sensorineural Hearing Loss (SNHL) and tinnitus intensity from the beginning to the end of the therapy. All patients received sterilized isotonic solution at high pressure (pression emission level: PEL): 7 g/sec for 0.5 sec (emission time: ET) in both nostrils. 25 minutes later a similar stimulation was delivered twice a day. The control group (21 pts) received normal therapy with betahistine dihydrochloride 16 mg twice a day.
  
  
  CONCLUSIONS
  Upon acuphenometry, there was a lower intensity of tinnitus and the improvement was signaled by the patients. Patients with SNHL treated with conventional therapy had a slight worsening, while the patients treated with our new therapy which increased NGF levels, showed improvement of hearing. This new therapy represents a new therapy of SNHL, tinnitus and hearing disorders.
authors.affiliation: Department of Otolaryngology, Campus Bio-Medico University, School of Medicine, Rome, Italy. v.frari@unicampus.it.
authors.forename: F
authors.initials: F
authors.lastname: Salvinelli
authors.forename: V
authors.initials: V
authors.lastname: Frari
authors.forename: M L
authors.initials: ML
authors.lastname: Rocco
authors.forename: P
authors.initials: P
authors.lastname: Rosso
authors.forename: L
authors.initials: L
authors.lastname: Aloe
mesh_terms: D000328:Adult; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007552:Isotonic Solutions / Q000008:administration & dosage*; D008297:Male; D008407:Mast Cells / Q000378:metabolism*; D008875:Middle Aged; D009296:Nasal Cavity / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000096:biosynthesis*; D010256:Paranasal Sinuses / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D011312:Pressure; D014012:Tinnitus / Q000175:diagnosis / Q000628:therapy*
chemical_list: D007552:Isotonic Solutions; D020932:Nerve Growth Factor